SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.75% Stake in Enlivex Therapeutics

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a beneficial ownership of 9.75% of Enlivex Therapeutics Ltd.'s Ordinary Shares as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Enlivex Therapeutics Ltd.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 2,208,000 Ordinary Shares of Enlivex Therapeutics Ltd.
• This ownership represents 9.75% of the total outstanding Ordinary Shares of the issuer.
• Both Armistice Capital, LLC and Steven Boyd hold shared voting and shared dispositive power over all 2,208,000 shares.
• Armistice Capital, LLC is identified as an investment adviser (IA), and Steven Boyd as a hedge fund (HC) and individual (IN).
• The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, consistent with a Rule 13d-1(b) filing.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the company's performance or prospects. It simply reports a significant stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional stake (9.75%) by Armistice Capital and Steven Boyd may influence market perception and investor confidence in Enlivex Therapeutics Ltd.

Key Dates

Keywords

Enlivex Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Ordinary Shares, Investment Adviser, Institutional Investor, M4130Y106